SDSaso Dohcev

Saso Dohcev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saso Dohcev has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kidney transplantation in Alport syndrome: A genotype-guided case series and literature review

    by Aleksandra Gavrilovska- Brzanov, Haris Sulejmani, Sasho Dohcev, Goce Spasovski, Nikola Georgievski, Aleksandar Trifunovski, Dimitar Trajkovski, Marija Jovanovski Srceva, Nikola Brzanov

    Kidney transplantation in Alport syndrome: A genotype-guided case series and literature review - Turkish Journal of Surgery


  • Open Access

    CHRONIC INFLAMMATION IN DIALYSIS PATIENTS AND ITS CORRELATION WITH DERMATOLOGICAL MANIFESTATIONS: A MULTICENTER STUDY FROM SKOPJE

    by Ivana Dohcheva Karajovanov, Suzana Nikolovska, Katerina Damevska, Vesna Velic Stefanovska, Sasho Dohchev, Silvija Duma, Hristina Breshkovska, Elena Mirceska Arsovska, Kosta Dohchev, Goce Spasovski, et al.

    Introduction: Chronic systemic inflammation is a defining feature in dialysis patients, contributing significantly to dermatological manifestations such as pruritus, xerosis, pigmentation changes, and nail abnormalities. These conditions impair quality of life and are linked to markers of systemic inflammation and dialysis-related factors. Objectives: This study aimed to analyze the prevalence and severity of dermatological manifestations in dialysis patients, and their correlations with systemic inflammation. Methods: An observational, cross-sectional study was conducted in two dialysis centers in Skopje, North Macedonia, involving 167 chronic dialysis patients. Data collection included dermatological assessments, laboratory markers (e.g., CRP, PTH, MPV), and pharmacological histories. Statistical analyses were used to explore correlations. Results: Pruritus was observed in 74% of patients and correlated significantly with CRP (R=0.223, p=0.005) and PTH (R=0.219, p=0.008). Xerosis affected 88.62% of patients, with moderate severity in 38.92%, and correlated with CRP (R=0.215, p=0.003). Pigmentation changes (63.47%) were linked to MPV (R=0.219, p=0.004), while nail abnormalities (81.44%) correlated with ferritin (R=0.170, p=0.028). Conclusion: Dermatological manifestations are prevalent in dialysis patients and closely associated with systemic inflammation markers. A multidisciplinary approach is essential to improve management and patient outcomes.

  • Open Access

    AHNAK2 Urinary Protein Expression as Potential Biomarker for Bladder Cancer Detection: A Pilot Study

    by Selim Komina, Gordana Petrusevska, Rubens Jovanovic, Slavica Kostadinova Kunovska, Sotir Stavridis, Saso Dohcev, Skender Saidi, Sonja Topuzovska

    Objective: This study aimed to measure the AHNAK2 urinary levels in bladder cancer patients. Material and methods: This prospective case–control study enrolled 67 participants between January and March 2019 and were categorized into bladder cancer group (n=37), with histologically proven bladder cancer, and control group (n=30), with histologically verified benign lesions or with no bladder cancer indication during follow-up. Urine samples of 15 mL were collected in the mid-morning before cystoscopy/surger y and an enzyme-linked immunosorbent assay was performed as per the manufacturer’s protocol. Bladder malignancies were classified according to the World Health Organization Tumor Classification. Group’s associations were evaluated with the Student t-test, Spearman’s rank correlation, and Mann–Whitney U test, while receiver operating curve was plotted for assessing the test’s performance. Results: Mean age of the bladder cancer group was 66.41 years (standard deviation=10.04, range=43-82 years) and the control group was 59.67 years (standard deviation=10.44, range=38-77 years). All bladder cancers were of the urothelial histotype, with the following pT distribution: pTa/papillary urothelial neoplasm of low malignant potential (n=19; 28.4%), Primary tumor (pT) in situ (n=4; 6%), pT1 (n=7; 10.4%), and pT≥2 (n=7; 10.48%). Mean AHNAK2 levels were higher in bladder cancer patients 49.08 pg/mL (standard deviation=114.91) compared to controls 5.28 pg/mL (standard deviation=6.65), P < .05). Significant differences were noted between non-invasive bladder cancer (n=23; mean=7.14 pg/mL; standard deviation=7.26) and invasive bladder cancer (n=14; mean=117.99 pg/mL; standard deviation=168.08) and between non-muscle invasive bladder cancer (mean=23.19 pg/mL; standard deviation=66.93) and muscle-invasive bladder cancer (mean=160.05 pg/mL; standard deviation=199.65) (P < .001). The result of the assays was given as follows: sensitivity: 64.19%, specificity: 66.67%, positive predictive value: 22.07%, negative predictive value: 92.37%, area under curve: 0.695, and 95% CI: 0.57-0.82. Conclusion: AHNAK2 protein could be used as bladder cancer surveillance biomarker. The inclusion of AHNAK2 levels in stratification nomograms might reduce the number of unnecessary cystoscopies. Cite this article as: Komina S, Petrusevska G, Jovanovic R, et al. AHNAK2 urinary protein expression as potential biomarker for bladder cancer detection: A pilot study. Turk J Urol. 2022;48(6):423-430.